Mounjaro 30mg

Mounjaro (Tirzepatide) | 30mg

When it comes to metabolic science, Mounjaro represents a genuine step change. Tirzepatide is the world’s first dual GIP and GLP-1 receptor agonist — a first-in-class compound developed by Eli Lilly that targets two distinct but complementary hormonal pathways simultaneously, delivering results that consistently outperform single-receptor approaches in clinical trials.

What Research Suggests Mounjaro May Support:

Significant Weight Reduction — Clinical trial data from the SURMOUNT programme demonstrated average weight reductions of up to 20.9% at the 10mg dose over 72 weeks — results that meaningfully exceed those seen with semaglutide in comparable trials, with the majority of participants achieving reductions of 15% or more.

Blood Sugar & Glycaemic Control — In the SURPASS-2 trial, tirzepatide reduced HbA1c by up to 2.30% compared to 1.86% with semaglutide — outperforming it at every dose tested, establishing Mounjaro as a leading compound in type 2 diabetes management research.

Appetite Regulation & Satiety — By acting on both GLP-1 and GIP receptors, Mounjaro reduces appetite, slows gastric emptying, and increases satiety signals — supporting sustained reductions in food intake across the full duration of research protocols.

Diabetes Prevention — In a landmark long-term study, weekly tirzepatide administration reduced the risk of progression to type 2 diabetes by over 90% in adults with prediabetes and obesity over 176 weeks — with nearly all participants remaining diabetes-free at the end of the study.

Cardiovascular & Cardiometabolic Health — Research points to meaningful improvements in waist circumference, systolic and diastolic blood pressure, fasting insulin, total cholesterol, LDL, and triglyceride levels — establishing a broad cardiometabolic benefit profile well beyond glycaemic management alone.

Lipid Profile Optimisation — Studies demonstrate reductions in total cholesterol, low-density lipoprotein, and triglycerides alongside increases in HDL cholesterol — pointing to a comprehensive and favourable impact on the lipid parameters most closely associated with cardiovascular risk.